Mutational profile
| Key molecular mutations . | HMA + VEN . | HMA . | Intensive induction . |
|---|---|---|---|
| Median mutations per patient (range) | 4 (1-9) | 4 (1-7) | 3 (1-11) |
| FLT3-ITD | 4 (18) | 28 (60) | 100 (44) |
| AR >0.5, n (by age, y) | |||
| <55 | — | — | 9 |
| 55-65 | — | 1 | 5 |
| >65 | — | 7 | 3 |
| AR <0.5, n (by age, y) | |||
| <55 | — | — | 45 |
| 55-65 | 1 | 2 | 27 |
| >65 | 3 | 18 | 10 |
| Total evaluable FLT3-ITD | 4/4 (100) | 28/28 (100) | 99/100 (99) |
| FLT3-D835 | 3 (7) | 5 (11) | 42 (18) |
| DNMT3A | 14 (50) | 18 (38) | 62 (27) |
| FLT3/DNMT3A | 1 (4) | 13 (28) | 30 (13) |
| IDH1 | 7 (25) | 9 (20) | 28 (12) |
| IDH2 | 7 (25) | 7 (15) | 44 (19) |
| Key molecular mutations . | HMA + VEN . | HMA . | Intensive induction . |
|---|---|---|---|
| Median mutations per patient (range) | 4 (1-9) | 4 (1-7) | 3 (1-11) |
| FLT3-ITD | 4 (18) | 28 (60) | 100 (44) |
| AR >0.5, n (by age, y) | |||
| <55 | — | — | 9 |
| 55-65 | — | 1 | 5 |
| >65 | — | 7 | 3 |
| AR <0.5, n (by age, y) | |||
| <55 | — | — | 45 |
| 55-65 | 1 | 2 | 27 |
| >65 | 3 | 18 | 10 |
| Total evaluable FLT3-ITD | 4/4 (100) | 28/28 (100) | 99/100 (99) |
| FLT3-D835 | 3 (7) | 5 (11) | 42 (18) |
| DNMT3A | 14 (50) | 18 (38) | 62 (27) |
| FLT3/DNMT3A | 1 (4) | 13 (28) | 30 (13) |
| IDH1 | 7 (25) | 9 (20) | 28 (12) |
| IDH2 | 7 (25) | 7 (15) | 44 (19) |
Data are n (%) or n/N (%) unless otherwise noted.